ViaCyte Funding & Investors
About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. About ViaCyte’s Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte’s PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.
viacyte.comTotal Amount Raised: $235,545,776
ViaCyte Funding Rounds
Series D
$80,000,000
Series D Investors
Sanderling VenturesBain Capital Life SciencesRA Capital ManagementTPGSeries D
$80,000,000
Series D Investors
Sanderling VenturesBain Capital Life SciencesRA Capital ManagementTPGSeries D
$32,645,780
Series D Investors
Sanderling VenturesBain Capital Life SciencesTPG Capital AsiaRA Capital ManagementSeries D
$32,645,780
Series D Investors
Sanderling VenturesBain Capital Life SciencesTPG Capital AsiaRA Capital ManagementConvertible Note
$10,000,000
Convertible Note Investors
W. L. Gore & AssociatesGrant
$1,400,000
Grant Investors
California Institute for Regenerative MedicineSeries Unknown
$10,000,000
Series Unknown Investors
W. L. Gore & AssociatesJDRFAsset Management PartnersSeries C
$10,600,000
Series C Investors
Johnson & Johnson DevelopmentSanderling VenturesConvertible Note
$10,000,000
Convertible Note Investors
W. L. Gore & AssociatesSeries Unknown
$10,000,000
Series Unknown Investors
W. L. Gore & AssociatesJDRFAsset Management PartnersGrant
$1,400,000
Grant Investors
California Institute for Regenerative MedicineSeries Unknown
$20,000,000
Series Unknown Investors
JanssenJohnson & Johnson InnovationSeries C
$5,400,000
Series C
$25,000,000
Series C Investors
Johnson & Johnson DevelopmentSanderling VenturesAsset Management VenturesPacific Horizon VenturesSeries Unknown
$20,000,000
Series Unknown Investors
Headland VenturesSanderling VenturesJohnson & Johnson DevelopmentThe Vertical GroupAsset Management VenturesBD VentureDFJ Portage VenturesPacific Horizon VenturesGrant
$3,900,000
Grant
$16,600,000
Grant Investors
California Institute for Regenerative MedicineSeries Unknown
$20,000,000
Series Unknown Investors
JanssenJohnson & Johnson InnovationSeries C
$5,400,000
Series C
$10,600,000
Series C Investors
Johnson & Johnson DevelopmentSanderling Ventures